Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of viral and host factors in interferon based therapy of hepatitis C virus infection.

Virology journal - 1 Oct 2013

Imran Muhammad, Manzoor Sobia, Ashraf Javed, Khalid Madiha, Tariq Muqddas, Khaliq Hafiza Madeha, Azam Sikandar

Abstract excerpt

The current standard of care (SOC) for hepatitis C virus (HCV) infection is the combination of pegylated interferon (PEG-IFN), Ribavirin and protease inhibitor for HCV genotype 1. Nevertheless, this treatment is successful only in 70-80% of the patients. In addition, the treatment is not economical and is of immense physical burden for the subject. It has been established now, that virus-host interactions play a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Genetic Markers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Interferons

Share to Prognosis

Share to Ribavirin

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 24079723
DOI: 10.1186/1743-422X-10-299
PMCID: PMC3849893

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of viral and host factors in interferon based therapy of hepatitis C virus infection.PMID 24079723Read ↗

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsSemantic proximity Read ↗

Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.Semantic proximity Read ↗

The role of viral and host genetics in natural history and treatment of chronic HCV infection.Semantic proximity Read ↗

Pharmacogenetics of hepatitis CSemantic proximity Read ↗

Host genomics and HCV personalized medicine.Semantic proximity Read ↗

Host genomics and HCV treatment response.Semantic proximity Read ↗

Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin.Semantic proximity Read ↗

Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.Semantic proximity Read ↗

IL28B polymorphism -- predictive factor of HCV infected genotype 1 individuals to treatment response and management of therapy.Semantic proximity Read ↗

The role of pharmacogenetics in the treatment of chronic hepatitis C infection.Semantic proximity Read ↗

Novel findings for the development of drug therapy for various liver diseases: Genetic variation in IL-28B is associated with response to the therapy for chronic hepatitis C.Semantic proximity Read ↗

Effect of IL28B genotype on hepatitis B and C virus infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.